Evaluating delays in patients treated with post-operative radiation therapy for head and neck squamous cell carcinoma

Ravi Marwah,1 Daniel Goonetilleke,1 Justin Smith1,2 and Madhavi Chilkuri1,2
1 Townsville University Hospital, Townsville, Queensland, Australia
2 James Cook University, Townsville, Queensland, Australia

Abstract

Introduction: Delays in commencing post-operative radiation therapy (PORT) and prolongation of overall treatment times (OTT) are associated with reduced overall survival and higher recurrence rates in patients with head and neck squamous cell carcinoma (HNSCC). The objective of this study was to evaluate treatment delays, factors contributing to those delays and to explore strategies to mitigate them.

Methods: This retrospective study included patients with mucosal HNSCC at Townsville University Hospital treated with curative intent surgery and PORT between June 2011 and June 2019. The proportion of patients who experienced delays in commencing PORT (>6 weeks) and OTT were evaluated and reasons for these delays were explored.

Results: The study included 94 patients of which 70% experienced PORT delay. Surgery at an external facility (81% vs 56%, \(P = 0.006\)) and longer post-operative length of stay (\(P = 0.011\)) were significantly associated with a higher incidence of PORT delay. Aboriginal and Torres Strait Islander patients had a higher rate of PORT delay (89% vs 68.2%, \(P = 0.198\)). Significant delays were noted from time of surgery to radiation oncology (RO) consult and from RO consult to commencement of radiation treatment.

Conclusion: This study demonstrates that the prevalence of PORT delay for patients with HNSCC remains high with room for improvement. Potential strategies to improve delays include developing effective care coordination, addressing specific needs of Indigenous patients, implementing reliable automated tracking and communication systems between teams and harnessing existing electronic referral systems.

Key words: head and neck cancer; post-operative radiotherapy; radiation therapy; treatment delays.

Introduction

Head and neck cancers include cancers of the pharynx, larynx, paranasal sinuses, nasal and oral cavity, with the most common histological type being squamous cell carcinoma.1 Advanced stage head and neck squamous cell carcinoma (HNSCC) is managed curatively with primary surgery and post-operative radiation therapy (PORT) or chemoradiation.2

Although not randomised, several studies have demonstrated that delay in commencing PORT is associated with reduced survival and higher recurrence rates.3–5 Therefore, guidelines nationally and internationally recommend commencing PORT within 6 weeks from surgery.6–8 Time to PORT ≤6 weeks has also been proposed as a quality indicator for national benchmarking in several countries.3,9–10 However, there is wide variation in its adherence, with PORT delay rates of 55.7%9 and 61%3 reported in two large national database studies conducted in the United States. A 2014 national audit of England and Wales also reported a median time to PORT of 50 days.10 The only study evaluating PORT delays in Australia reported a delay rate of 62%.11 In addition to delay in PORT, several studies have also linked prolonged overall treatment time (OTT; surgery to completion of PORT) to worse patient outcomes.4,12,13 However, there is no consensus regarding an optimal time threshold, with studies reporting a wide range from 77 to
100 days. Studies exploring reasons for PORT delay in the United States have identified a variety of associated factors such as black race, poor communication between care providers, longer post-operative lengths of stay, and receipt of surgery and PORT at different facilities. However, there are no studies that have explored the reasons for PORT delay in Australia, which has a vastly different health system from the United States. The aim of this study was to evaluate treatment delays in patients with HNSCC, to determine the factors associated with these delays and to explore potential solutions to minimise these delays.

**Methods**

**Study design**

This was a single-institution retrospective chart review of patients over 18 years with mucosal HNSCC patients who received PORT between June 2011 and June 2019. All patients received PORT at Townsville University Hospital (TUH), a regional tertiary hospital in North Queensland, except one that was referred to another facility in the same region. Primary surgery was performed at either TUH or at one of two external metropolitan referral centres in Brisbane, approximately 1300 km south of Townsville. Patients with synchronous malignancies outside the head and neck region were excluded. This study follows an earlier study that reported quality indicators in head and neck cancer and identified time to PORT as an area for improvement at our institution. Ethics approval for this study was granted by the Institutional Human Research Ethics Committee (HREC/QTHS/67801).

**Data collection**

Data were extracted from iEMR and MOSAIQ oncology management information system (OIMS) and entered into RedCap database. Data extracted included various patient characteristics including age, sex, date of birth, smoking status, ethnicity, Charlson Comorbidity Index and living distance from hospital. Tumour characteristics collected included tumour site, HPV status, TNM stage (AJCC 7th edition) and extranodal extension. Treatment details included date of diagnosis, dental workup requirement, surgery location, surgical margins, date of histopathology reporting, post-operative interruptions, post-operative length of stay, re-admission following surgery, date of post-operative referral, concurrent chemotherapy, interruptions of radiation therapy (RT) and the dates of various treatment time points. The date of referral was considered the date a post-operative referral letter was received. However, for those that were referred pre-operatively and had surgery at TUH, the date of referral was considered the date of the post-operative multidisciplinary team meeting when the patients were reviewed by a radiation oncologist.

**Statistical analyses**

Data were analysed using Stata V16 with the level of significance set at \( P < 0.05 \). Descriptive statistics were used to report the percentage of head and neck cancer patients with PORT delay (>42 days). Factors associated with PORT delays were analysed using a Chi squared test for categorical variables and Mann-Whitney \( U \) test for continuous variables.

**Results**

There were 94 patients included in the study. 70% (66/94) of patients were found to have a PORT delay (time to PORT >42 days) with the median time to PORT of 48 days.

**Factors associated with PORT delay**

Surgery at an external facility was significantly associated with PORT delay. The PORT delay rate at external facilities was 81% vs 56% at TUH (\( P = 0.008 \)). Similarly, a longer post-operative length of stay was significantly associated with PORT delay (13 days vs 7.5 days, \( P = 0.011 \)). Aboriginal and Torres Strait Islander patients had a higher rate of PORT delay than their non-indigenous counterparts although this difference was not statistically significant (89% vs 68.2%, \( P = 0.198 \)) (Table 1).

**Care processes associated with PORT delay**

Median time from surgery to RO consult was 22 days, while median time from RO consult to PORT commencement was 26 days. Median time from RT planning to PORT start for the entire study cohort was 19 days.

Exploring these processes further, we found that of the entire study cohort, 53% (50/94) of patients had a surgery to RO consult time of greater than 3 weeks and 61% (57/94) had RO consult to PORT commencement greater than 3 weeks (Table 2) with 30% (28/94) of patients having greater than 3 weeks in both these processes. Similarly, 27% (25/94) of patients had a surgery to RO consult time of greater than 4 weeks and 30% (28/94) had RO consult to PORT commencement greater than 4 weeks. (Table 2) with 6% (6/94) of patients having greater than 4 weeks in both these processes. Given the delay associated with surgery at external facilities, care processes were further explored for this subset of patients. As shown in Table 3, median time of post-operative length of stay (13 days vs 7 days, \( P = 0.03 \)), surgery to RO Consult (27 days vs 15 days, \( P < 0.001 \)) and discharge to RO Consult time periods (12 days vs 6 days, \( P < 0.001 \) were all significantly longer with surgery at external facilities. Similarly, surgery to referral (19 days vs 12 days, \( P < 0.001 \)), histopathology reporting
to referral (13 days vs 1 day, \( P < 0.001 \)) and referral to RO consult (7 days vs 0 days, \( P < 0.001 \)) were also significantly longer with surgery at external facilities.

### Table 1. Factors associated with PORT delay

| Study cohort \((n = 94)\) | PORT delay \( (>42 \text{ days}) \) | \( P \) value |
|---------------------------|---------------------------------|-------------|
| **Patient characteristics** |                                 |             |
| Sex                       |                                 |             |
| Male                      | 56/78 (71.8%)                   | 0.459       |
| Female                    | 10/16 (62.5%)                   |             |
| Age†                      | 59.4 ± 9.4 vs 59.3 ± 12.6       | 0.98        |
| Ethnicity                 |                                 |             |
| Aboriginal and/or Torres Strait Islander | 8/9 (88.9%) | 0.198       |
| Not Aboriginal and/or Torres Strait Islander | 58/85 (68.2%) |           |
| Distance from Townsville Hospital | 40/53 (75.5%) | 0.205       |
| ≥200 km                   | 26/41 (63.4%)                   |             |
| <200 km                   | 23/33 (69.7%)                   |             |
| Smoking status            |                                 |             |
| Current                   | 39/51 (76.5%)                   | 0.07        |
| Former                    | 4/10 (40%)                      |             |
| Charlson Comorbidity Index‡|                                 |             |
| ≤1                        | 23/36 (63.9%)                   | 0.291       |
| >1                        | 43/58 (74.1%)                   |             |
| **Tumour characteristics** |                                 |             |
| Tumour site               |                                 |             |
| Nasal cavity              | 2/3 (66.7%)                     | 0.202       |
| Oral cavity               | 41/53 (77.4%)                   |             |
| Oropharynx                | 8/14 (57.1%)                    |             |
| Hypopharynx               | 10/13 (76.9%)                   |             |
| Larynx                    | 5/11 (45.5%)                    |             |
| Tumour stage              |                                 |             |
| Early stage               | 5/10 (50%)                      | 0.139       |
| Late stage                | 61/84 (72.6%)                   |             |
| Extranodal extension      |                                 |             |
| Yes                       | 25/31 (80.7%)                   | 0.121       |
| No                        | 4/10 (40%)                      |             |
| Treatment                 |                                 |             |
| Surgery location          |                                 |             |
| External                  | 43/53 (81.1%)                   | 0.008       |
| Internal                  | 23/41 (56.1%)                   |             |
| Surgical margins          |                                 |             |
| Positive                  | 9/12 (75%)                      | 0.698       |
| Negative                  | 57/82 (69.5%)                   |             |
| Post-operative Length of Stay‡| 13 days (12) vs 7.5 days (9.5) | 0.011       |
| Re-admission following surgery | 5/6 (83.3%) | 0.448       |
| Yes                       | 5/8 (68.6%)                     |             |
| No                        | 27/34 (79.4%)                   | 0.142       |
| Post-operative chemotherapy|                                 |             |
| Yes                       | 20/25 (80%)                     | 0.212       |
| No                        | 39/60 (65%)                     |             |
| Pre RT Dental work up required | 46/69 (66.7%) |           |

†Mean ± SD, comparison to no PORT delay group.
‡Median (IQR), comparison to no PORT delay group.

### Table 2. PORT delays in relation to care processes

| Time to PORT† | Overall | 48 days (19) |
|---------------|---------|--------------|
| PORT delay (>42 days)‡ | Yes – 66 (70.2%) | No – 28 (29.8%) |
| Surgery to RO consult† | 22 days (14) | 26 days (13) |
| • Surgery to RO Consult >3 weeks | 50 (53.2%) | 25 (26.6%) |
| • Surgery to RO Consult >4 weeks | 57 (60.6%) | 28 (29.8%) |
| RO Consult to PORT Start† | 45 days (8) | 19 days (9) |
| • RO Consult to PORT Start >3 weeks | | |
| • RO Consult to PORT Start >4 weeks | | |
| Planning to PORT Start† | | |

†Median number of days (IQR).‡Number of patients (%).

### Table 3. PORT delay: surgery at TUH vs external facility

| TUH | External | Overall | \( P \) value |
|-----|----------|---------|---------------|
| Post-operative length of stay† | 7 days (10) | 13 days (12) | 10 days (10) | 0.003 |
| Surgery to RO consult† | 15 days (10) | 27 days (13) | 22 days (14) | <0.001 |
| Surgery to referral† | 12 days (10) | 19 days (12) | 15 days (10) | <0.001 |
| Surgery to histopathology† | 8 days (6) | 5 days (2) | 6 days (4) | <0.001 |
| Histopathology to referral† | 1 days (7) | 13 days (11) | 8 days (14) | 0.001 |
| Referral to RO consult† | 0 days (7) | 7 days (9) | 5 days (11) | <0.001 |
| Discharge to RO consult† | 6 days (10) | 12 days (9) | 10 days (9) | <0.001 |
| RO consult to PORT Start† | 27 days (12) | 24 days (14) | 26 days (13) | 0.323 |

†Median number of days (IQR).
Statistically significant values are bold values.

### Table 4. Overall treatment time

| OTT | Number of patients (%) |
|-----|------------------------|
| <77 days | 13 [13.8%] |
| 78–84 days | 21 [22.3%] |
| 85–91 days | 21 [22.3%] |
| 92–98 days | 15 [16%] |
| >98 days | 24 [25.5%] |

**Overall treatment time**

The median OTT was 86 days. OTT was greater than 13 weeks (91 days) in 41% (39/94) of patients, while 26% (24/94) of patients had OTT of greater than 14 weeks (98 days) (Table 4).

**Factors associated with prolongation of OTT**

Of all patients, 21% (20/94) had unplanned prolongation of their radiation treatment. The reasons included patient...
non-compliance, machine breakdown and failure to compensate for unplanned treatment delays from public holidays and treatment starting mid-week. Only 14% (9/66) of patients with PORT delay (>42 days) were treated with altered fractionation.

Discussion

This study reports a PORT delay rate of 70% which is higher than rates reported in the literature (55.7–62%). Our study found that surgery at an external facility was associated with a higher incidence of PORT delay compared with receiving surgery at TUH. Given patients requiring complex surgery are referred to an external facility, post-operative complications leading to prolonged post-operative stay (median; 13 days) in these patients are not unexpected. However, this alone was not the cause of delayed PORT. Patients had significantly longer delays in post-operative referrals and radiation oncology consults. Graboyes et al. and Harris et al. reported that patients who received surgery and PORT at different facilities were more likely to experience delayed PORT. Graboyes et al. hypothesised that this may be due to insufficient care coordination and communication during care transitions, with providers facing the difficult task of reconciling differing electronic and paper-based health records. Janz et al. suggested that patients experiencing care fragmentation may also be more likely to experience PORT delays due to their inability to receive initial radiation oncology consults during their surgical admission. Only one study to date has offered a potential solution for fragmentation of care.

This study utilised cancer care coordinators/navigators with multiple roles including systematically tracking referrals, as well as ensuring appointment scheduling and patient attendance, achieving a low PORT delay rate of only 14%. While organisations might be reluctant to invest in such interventions due to cost, it is important to recognise the significant financial burden that is associated with poor patient outcomes.

When care processes for all patients with delayed PORT were evaluated, we found that there were significant delays from time of surgery to RO consult and from RO consult to initiation of treatment, with several patients experiencing delay in both care processes. Post-operative complications, patient non-compliance and delayed/extensive pre-radiation dental extractions can contribute to delays from radiation oncology consult to PORT. While these factors were noted in our study, there were other avoidable factors such as prolonged consult to planning, prolonged planning to treatment and failure to compensate for unscheduled treatment interruptions that impacted both delay in PORT commencement and OTT. We should recognise that while there will be unavoidable delays in at least some patients, avoidable delays must be minimised. A prospective randomised trial by Ang et al. found that time to PORT was greater than 42 days in only 9% of patients, and this was due to slow wound healing, fistula or bone exposure, laryngeal oedema or aspiration and poor compliance.

For those that have had delays in commencement of PORT, attempts should be made to reduce the OTT. Retrospective studies have demonstrated an optimal OTT of 77–100 days while analysis from a prospective randomised trial found inferior outcomes with OTT beyond 77–91 days, with OTT of >91 days especially detrimental when treatment initiation was delayed beyond 42 days.

With OTT greater than 91 days in 42% of our patient cohort, this is an area for improvement. Altered fractionation (accelerated radiotherapy, hyper-fractionation) has been shown to improve locoregional control with acceptable acute toxicities and comparable late toxicities when compared to conventional fractionation, although a survival benefit has not been established. The Royal College of Radiologists (RCR) recommends compensatory measures (such as acceleration and/or increasing the dose per fraction) to minimise the effects of prolongation of treatment from unscheduled treatment interruptions. As part of clinical benchmarking in radiation oncology to improve quality of care and clinical outcomes, prolongation of treatment times in RCR category 1 cancers (includes head and neck cancers) is monitored and reported nationally in Australia. In 2019, prolongation of treatment time by more than 2 days was found in 12.5% of patients though the institutions reporting this quality metric was low. In the UK, this metric has been set at <5% by RCR.

Lastly, but most importantly, almost all (8 of 9) Indigenous patients had PORT delay. Indigenous patients have lower 5-year survival rates (66% vs 41.5%) for HNSCC than non-indigenous people. There has been no research to explore PORT delays in Aboriginal and Torres Strait Islander patients. However, a few studies have explored the reasons for poorer access to cancer treatment services in Indigenous Australians. Lyford et al. and Anderson et al. highlighted fear or lack of trust of mainstream health facilities, poor communication by healthcare providers, fatalistic beliefs about cancer, cultural insensitivity and lack of culturally relevant care, and difficulties navigating the health system as some reasons. Numerous interventions for improving accessibility to cancer treatment services have been suggested in the literature, focusing mainly on the following three domains: providing culturally appropriate and safe care (e.g. early involvement of Indigenous Health Workers and liaison officers and mandatory cultural awareness training for health workers), improving cancer knowledge in the Indigenous community (e.g. development of culturally appropriate educational resources) and cancer care coordination/navigation.

The 42-day cut-off for commencement of PORT is based on retrospective studies and a meta-analysis. It is not likely that randomised studies will be conducted to establish an alternative metric other than
42 days. In addition to the ethical dilemma of conducting such studies, there is convincing evidence of inferior outcomes with delays in treatment. Studies have shown that rate of delay in PORT commencement can be reduced to <15%.4,24 Therefore, this should be a metric for benchmarking for all facilities.

To achieve timeliness of PORT, facilities should track and manage process time periods. There has only been one study that has attempted to standardise care process time periods, although no consensus guidelines exist.18 This study recommended surgery to PORT referral within 10 days, PORT referral to radiation oncology consult within 10 days, and radiation oncology consultation to PORT commencement within 21 days.18 These timelines are achievable, however require effective communication and coordination of care within and between teams. The care process timeframes should be flexible in the event of delay in one or more steps of the care pathway. Surgical teams, particularly external facilities, should aim to complete referrals as soon as histopathology report is available and should involve the care coordinators at every step of the process. Indigenous and Torres Strait Islander patients should be appropriately supported, and Indigenous liaison officers/coordinators should be involved through all care processes.

Multidisciplinary teams meet weekly at TUH and the two external facilities. Improving communication and coordination of care by utilising existing electronic record platforms to generate electronic referrals at the first post-operative review in the head and neck multidisciplinary clinic, tracking patient progress through automated reminders to care coordinators and clinical teams and including a ‘must treat by’ option when booking radiation treatment are feasible and are being implemented at our institution. Educating the treating teams of the importance of timeliness of PORT, pre-operative radiation oncology consult when appropriate, patient education on the importance of compliance to PORT at initial consult,15,32 pre-operative dental evaluations with intraoperative extractions,33 compensation for unplanned radiation treatment prolongation and altered fractionation in those experiencing delays are other important considerations to ensure timely PORT.21-24

**Limitations**

The major limitation of this study is that it is a retrospective study with its inherent selection bias and unknown confounders. Exploring the reasons for treatment delays was limited by the data recorded in the electronic medical records and therefore could not have captured all possible reasons and granularity of decision making. Given the small number of patients in the no PORT delay group, it is possible that further factors associated with PORT delays were unable to be established in this study. Given this was conducted at a single institution in Australia, it may not be generalisable. However, international studies have demonstrated similar barriers to achieving timely PORT. The study did not evaluate impact of delays on treatment outcome given the small sample size. Additionally, multiple studies have sufficiently demonstrated the negative impact of treatment delays on outcomes.

**Conclusion**

In conclusion, this study demonstrates that the rate of PORT delay remains high despite strong evidence to suggest that these delays contribute to poor patient outcomes. Clinical teams should evaluate their processes and develop strategies for a sustainable model of well-coordinated care, taking into consideration that potential interventions will need to be tailored to address the specific geographical, socio-demographic and cultural factors. Organisations should strive to benchmark care processes times and evaluate at least annually. Further research exploring health worker and patient perspectives on the causes of PORT delay and potential targets of intervention are urgently needed. These studies should not only consider the efficacy of their proposed interventions but also the cost-effectiveness.

**Acknowledgement**

Open access publishing facilitated by James Cook University, as part of the Wiley - James Cook University agreement via the Council of Australian University Librarians. Open access publishing facilitated by James Cook University, as part of the Wiley - James Cook University agreement via the Council of Australian University Librarians.

**Funding**

No sources of funding.

**Data availability statement**

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

**References**

1. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 2020; 6: 92.
2. Anderson G, Ebadi M, Vo K, Novak J, Govindarajan A, Amini A. An updated review on head and neck cancer treatment with radiation therapy. Cancer 2021; 13: 4912.
3. Harris JP, Chen MM, Orosco RK, Sirjani D, Divi V, Haran W. Association of survival with shorter time to radiation therapy after surgery for US patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg 2018; 144: 349–59.
4. Ang KK, Trotti A, Brown BW et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51: 571–8.

5. Franco R, Marta GN. Timing factors as prognostic variables in patients with head and neck squamous cell carcinoma treated with adjuvant radiotherapy: a literature review. Rev Assoc Med Bras 2020; 66: 380–4.

6. National Comprehensive Cancer Network. Head and Neck Cancers (Version 1.2016): National Comprehensive Cancer Network, 2016 [Accessed August 11, 2020]. Available from URL: https://www.cancer.org/acs/groups/cid/documents/document/acspc-052796.pdf [Accessed 19 December, 2021]. Available from: https://www.cancer.org/acs/groups/cid/documents/document/acspc-052796.pdf

7. Cancer Council Victoria & Department of Health Victoria. Optimal Care Pathway for People with Head and Neck Cancer, 2nd edn. Melbourne, Vic.: Cancer Council Victoria & Department of Health Victoria, 2021 [Accessed November 19, 2021]. Available from URL: https://www.cancer.org.au/assets/pdf/head-and-neck-cancers-optimal-cancer-care-pathway.pdf

8. Cancer Institute NSW. Head and Neck SCC EBRT Post-Operative with or without Chemotherapy: eviQ, 2019 [Accessed August 22, 2020]. Available from URL: https://www.eviq.org.au/radiation-oncology/head-and-neck/3390-head-and-neck-squamous-cell-carcinoma-adjuvan.pdf

9. Graboyes EM, Garrett-Mayer E, Sharma AK, Lentsch EJ, Day TA. Adherence to National Comprehensive Cancer Network guidelines for time to initiation of postoperative radiation therapy for patients with head and neck cancer. Cancer 2017; 123: 2651–60.

10. The National Head and Neck Cancer Audit Project Team. National Head and Neck Cancer Audit: Health and Social Care Information Centre, 2014 [Accessed January 10, 2022]. Available from URL: https://www.healthyaging.gov.uk/wp-content/uploads/2018/02/ueT19r.pdf

11. Venchiarutti RL, Clark JR, Palme CE et al. Influence of remoteness of residence on timeliness of diagnosis and treatment of oral cavity and oropharynx cancer: a retrospective cohort study. J Med Imaging Radiat Oncol 2020; 64: 261.

12. Guttmann DM, Kobie J, Grover S et al. National disparities in treatment package time for resected locally advanced head and neck cancer and impact on overall survival. Head Neck 2018; 40: 1147–55.

13. Swiwinski R, Sowa A, Rutkowski T, Wydmanski J, Tarnawski R, Maciejewski B. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys 2003; 56: 399–412.

14. Graboyes EM, Kompelli AR, Neskey DM et al. Association of treatment delays with survival for patients with head and neck cancer: a systematic review. JAMA Otolaryngol Head Neck Surg 2019; 145: 166–77.

15. Sykes KJ, Morrow E, Smith JB et al. What is the hold up?-mixed-methods analysis of postoperative radiotherapy delay in head and neck cancer. Head Neck 2020; 42: 2948–57.

16. Chilukuri M, Vangaveti V, Smith J. Head and neck cancers: monitoring quality and reporting outcomes. J Med Imaging Radiat Oncol 2021; 66: 455–65.

17. Graboyes EM, Halbert CH, Li H et al. Barriers to the delivery of timely, guideline-adherent adjuvant therapy among patients with head and neck cancer. JCO Oncol Pract 2020; 16: e1417–32.

18. Janz TA, Kim J, Hill EG et al. Association of care processes with timely, equitable postoperative radiotherapy in patients with surgically treated head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 2018; 144: 1105–14.

19. Graboyes EM, Sterba KR, Li H et al. Development and evaluation of a navigation-based, multilevel intervention to improve the delivery of timely, guideline-adherent adjuvant therapy for patients with head and neck cancer. JCO Oncol Pract 2021; 17: e1512–23.

20. Jurica JM, Rubio F, Hernandez DJ, Sandulache VC. Institutional financial toxicity of failure to adhere to treatment guidelines for head and neck squamous cell carcinoma. Head Neck 2021; 43: 816–24.

21. Awwad HK, Lotayef M, Shouman T et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer 2002; 86: 517–23.

22. Shah N, Saunders MJ, Dische S. A pilot study of postoperative CHART and CHARTWEL in head and neck cancer. Clin Oncol (R Coll Radiol) 2000; 12: 392–6.

23. Trotti A, Klotch D, Endicott J, Ridley M, Greenberg H. A prospective trial of accelerated radiotherapy in the postoperative treatment of high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1993; 26: 13–21.

24. The Royal College of Radiologists. The timely delivery of radical radiotherapy: guidelines for the management of unscheduled treatment interruptions: The Royal College of Radiologists, 2019 [4th edition; Accessed 25 October, 2021]. Available from URL: https://www.rcr.ac.uk/system/files/publication/field_publication_files/bfco191_radiotherapy-treatment-interruptions.pdf

25. Australian Council on Healthcare Standards. Australasian Clinical Indicator Report: Australian Council on Healthcare Standards, 2020 [21st edition; Accessed 14 January, 2022]. Available from URL: https://www3.achs.org.au/media/183244/acir_2012-2019_21st_ed.pdf

26. Australian Institute of Health and Welfare. Cancer in Aboriginal & Torres Strait Islander people of Australia: Australian Institute of Health and Welfare, 2018 [Accessed 19 December, 2021]. Available from: https://www.aihw.gov.au/reports/cancer/cancer-in-indigenous-australians/contents/cancer-type/head-and-neck-cancer-c00-c14-c30-c32

27. Lyford M, Haigh MM, Baxi S, Cheetham S, Shahid S, Thompson SC. An exploration of underrepresentation of aboriginal cancer patients attending a regional...
radiotherapy Service in Western Australia. *Int J Environ Res Public Health* 2018; **15**: 337.

28. Anderson K, Diaz A, Parikh DR, Garvey G. Accessibility of cancer treatment services for indigenous Australians in the Northern Territory: perspectives of patients and care providers. *BMC Health Serv Res* 2021; **21**: 95.

29. Taylor EV, Haigh MM, Shahid S, Garvey G, Cunningham J, Thompson SC. Cancer services and their initiatives to improve the Care of Indigenous Australians. *Int J Environ Res Public Health* 2018; **15**: 717.

30. Taylor EV, Lyford M, Holloway M et al. “The support has been brilliant”: experiences of aboriginal and Torres Strait islander patients attending two high performing cancer services. *BMC Health Serv Res* 2021; **21**: 493.

31. Huang J, Barbera L, Brouwers M, Brownman G, Mackillop WJ. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. *J Clin Oncol* 2003; **21**: 555-63.

32. Teng MS, Gupta V. Timely adjuvant postoperative radiotherapy: racing to a PORT in the storm. *JAMA Otolaryngol Head Neck Surg* 2018; **144**: 1114–5.

33. Divi V, Chen MM, Hara W et al. Reducing the time from surgery to adjuvant radiation therapy: an institutional quality improvement project. *Otolaryngol Head Neck Surg* 2018; **159**: 158–65.